Ultivue has announced a collaborative partnership with OracleBio to help further insights and advance personalised tumour characterisation in translational and clinical oncology research using multiplex immunofluorescence staining and imaging.
The deal connects the histopathology image analysis expertise of OracleBio and the tissue staining capabilities of Ultivue, with the goal of providing pharmaceutical companies with an end-to-end workflow for gaining valuable insights from biomarkers in situ.
OracleBio, a contract research organisation based in Scotland, is known for its quantitative digital pathology services, delivering high-quality image analysis while leveraging multiple software platforms in supporting clinical and preclinical research.
“OracleBio aims to deliver robust quantitative histopathology data deployed within a quality framework, and that analysis can be heavily dependent on the quality of sample preparation and staining,” says Lorcan Sherry (OracleBio CSO). “Being able to partner with Ultivue means we can be confident in the staining of the tissue we’re quantifying, which ultimately means more precise data.”
Cambridge, Massachusetts-based Ultivue develops reagents for staining tissues used for multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex technology is designed for fast and comprehensive exploration of biologically-relevant markers in tissue samples.
“We’ve developed reagents that are workflow-agnostic and can plug-and-play in most customers’ existing laboratory infrastructure, so it makes sense to partner with a like-minded imaging and analysis contract research organisation (CRO) like you have in OracleBio. At the end of the day, our goal is always to offer our customers relevant and meaningful biological insights from their samples, regardless of their preferred hardware or software,” says Jacques Corriveau (President and CEO, Ultivue).